Acacia Diversified Holdings, Inc. (ACCA)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Acacia Diversified Holdings, Inc. (ACCA) with AI Score 48/100 (Weak). Acacia Diversified Holdings, Inc. focuses on the extraction, processing, and distribution of medical-grade hemp oils and related products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Acacia Diversified Holdings, Inc. (ACCA) Healthcare & Pipeline Overview
Acacia Diversified Holdings, Inc. operates in the specialty and generic drug manufacturing sector, focusing on high-CBD/low-THC medical-grade hemp oils. The company engages in extraction, processing, research, development, and distribution of medicinal hemp products and dietary supplements under the EUFLORIA brand, primarily within the United States.
Investment Thesis
Acacia Diversified Holdings, Inc. presents a speculative investment opportunity within the high-growth CBD market. The company's focus on medical-grade hemp oils and nutraceuticals aligns with increasing consumer interest in alternative health solutions. However, the company's negative profit margin of -329.4% and small market capitalization of $0.00B indicate significant financial challenges. Key value drivers include successful product development and expansion of distribution channels. Growth catalysts involve regulatory changes favoring CBD products and increased consumer acceptance. Potential risks include intense competition, regulatory uncertainty, and the company's ability to secure funding for ongoing operations and research.
Based on FMP financials and quantitative analysis
Key Highlights
- Acacia Diversified Holdings, Inc. operates in the high-growth CBD market, focusing on medical-grade hemp oils.
- The company's gross margin is 4.9%, indicating potential challenges in profitability.
- Acacia's profit margin is -329.4%, reflecting significant losses.
- The company has a small team of 5 employees, suggesting a lean operational structure.
- Acacia's beta of -0.55 suggests a negative correlation with the broader market.
Competitors & Peers
Strengths
- Focus on high-CBD/low-THC medical grade hemp oils.
- Involvement in research and development of botanicals endocannabinoid nutraceuticals.
- Retail and wholesale distribution of medicinal hemp products.
- Consumer products offered under the EUFLORIA brand.
Weaknesses
- Negative profit margin of -329.4%.
- Small market capitalization of $0.00B.
- Limited number of employees (5).
- Dependence on the evolving regulatory environment for CBD products.
Catalysts
- Upcoming: Potential regulatory changes favoring CBD products could expand market access.
- Ongoing: Increasing consumer acceptance of CBD for health and wellness purposes.
- Ongoing: Expansion of distribution channels through strategic partnerships.
- Upcoming: Successful development and launch of new CBD-based products.
Risks
- Potential: Intense competition in the rapidly growing CBD market.
- Ongoing: Regulatory uncertainty surrounding CBD products and their distribution.
- Potential: Challenges in securing funding for ongoing operations and research.
- Ongoing: Fluctuations in the price and availability of hemp.
- Potential: Negative profit margin and limited financial resources.
Growth Opportunities
- Expansion of EUFLORIA Product Line: Acacia has the opportunity to expand its EUFLORIA brand product line to include a wider range of CBD-infused products, targeting various consumer needs such as skincare, pain relief, and sleep aids. The global CBD skincare market is projected to reach $3.48 billion by 2028, presenting a significant growth avenue. Successful product diversification and marketing could drive increased revenue and brand recognition for Acacia.
- Strategic Partnerships with Retailers: Forming strategic partnerships with established retailers, both online and brick-and-mortar, can significantly expand Acacia's distribution network. Collaborating with major health and wellness retailers or specialty CBD stores can provide access to a broader customer base and increase product visibility. The timeline for establishing such partnerships is estimated at 12-18 months, with potential revenue impact within 2-3 years.
- Geographic Expansion within the United States: Acacia can focus on expanding its operations to new states within the United States, particularly those with favorable regulatory environments for CBD products. Targeting states with high population densities and a growing interest in alternative health solutions can drive revenue growth. This expansion strategy could be implemented within the next 24 months, with potential revenue gains within 3-5 years.
- Research and Development of Novel CBD Formulations: Investing in research and development to create novel CBD formulations and delivery methods can provide a competitive edge. Developing innovative products such as fast-acting CBD patches, sublingual sprays, or enhanced bioavailability capsules can attract consumers seeking more effective and convenient solutions. The timeline for R&D and product development is estimated at 2-3 years, with potential market introduction within 3-5 years.
- Capitalizing on Regulatory Changes: Monitoring and adapting to evolving regulatory changes in the CBD industry is crucial for growth. As regulations become more standardized and favorable, Acacia can capitalize on opportunities such as expanding into new markets, developing new products, and establishing partnerships with larger pharmaceutical companies. The timeline for regulatory changes is uncertain, but proactive adaptation can provide a significant competitive advantage.
Opportunities
- Expansion of the EUFLORIA product line.
- Strategic partnerships with retailers.
- Geographic expansion within the United States.
- Research and development of novel CBD formulations.
Threats
- Intense competition in the CBD market.
- Regulatory uncertainty surrounding CBD products.
- Potential challenges in securing funding for ongoing operations.
- Fluctuations in the price and availability of hemp.
Competitive Advantages
- Proprietary extraction and processing techniques for high-CBD hemp oils.
- Established brand presence with the EUFLORIA product line.
- Focus on research and development of innovative CBD formulations.
About ACCA
Acacia Diversified Holdings, Inc., formerly known as Acacia Automotive, Inc., was incorporated in 1984 and rebranded in October 2012 to focus on the burgeoning market for medical hemp products. Based in Clearwater, Florida, the company specializes in the extraction and processing of medical-grade hemp oils, characterized by their high cannabidiol (CBD) and low tetrahydrocannabinol (THC) content. These oils are derived from medical hemp plants cultivated within the United States. Acacia's business extends beyond mere extraction; it is actively involved in the research and development of botanicals endocannabinoid nutraceuticals. This includes the creation of a diverse product line aimed at addressing various health and wellness needs. The company also manages the retail and wholesale distribution of its medicinal hemp products and dietary supplements, ensuring accessibility to a broad consumer base. A key aspect of Acacia's distribution strategy involves its consumer products marketed under the EUFLORIA brand name, which are sold through multiple distribution channels. With a small team of 5 employees, Acacia operates with a lean structure, emphasizing innovation and market responsiveness in the rapidly evolving cannabis industry. The company's focus on high-quality CBD products positions it to capitalize on the increasing acceptance and demand for alternative health solutions.
What They Do
- Extracts and processes high-CBD/low-THC content medical grade hemp oils.
- Conducts research and development of botanicals endocannabinoid nutraceuticals.
- Engages in retail and wholesale distribution of medicinal hemp products.
- Offers dietary supplements.
- Markets consumer products under the EUFLORIA brand name.
- Focuses on distribution through various channels.
Business Model
- Extraction and processing of medical-grade hemp oils.
- Research and development of CBD-based products.
- Sales of medicinal hemp products and dietary supplements through retail and wholesale channels.
Industry Context
Acacia Diversified Holdings, Inc. operates within the rapidly expanding market for specialty and generic drug manufacturers, specifically focusing on CBD-based products. The industry is characterized by increasing consumer demand for alternative health solutions and evolving regulatory landscapes. Competitors range from established pharmaceutical companies to smaller, specialized firms. The market is driven by factors such as the growing acceptance of cannabis-derived products for medicinal purposes and the increasing availability of CBD-based products through various retail channels. This competitive landscape requires companies like Acacia to differentiate themselves through product innovation, quality, and effective distribution strategies.
Key Customers
- Individuals seeking alternative health and wellness solutions.
- Retailers and wholesalers in the health and wellness industry.
- Consumers interested in CBD-based products for various health conditions.
Financials
Chart & Info
Acacia Diversified Holdings, Inc. (ACCA) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACCA.
Price Targets
Wall Street price target analysis for ACCA.
MoonshotScore
What does this score mean?
The MoonshotScore rates ACCA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jeffery D. Bearden
CEO
Jeffery D. Bearden serves as the CEO of Acacia Diversified Holdings, Inc., leading a small team of 5 employees. Information regarding his detailed career history, education, and previous roles is not available. As CEO, he is responsible for the overall strategic direction and operational management of the company, focusing on the extraction, processing, and distribution of medical-grade hemp oils and related products. His leadership is crucial in navigating the evolving regulatory landscape and competitive dynamics of the CBD market.
Track Record: Due to limited information available, specific achievements, strategic decisions, and company milestones under Jeffery D. Bearden's leadership cannot be detailed. His focus is on guiding Acacia Diversified Holdings, Inc. through the challenges and opportunities in the emerging CBD industry, with an emphasis on product development and market expansion.
ACCA OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Acacia Diversified Holdings, Inc. may not meet the minimum financial standards or disclosure requirements of the higher OTC tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and oversight compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for less transparency and regulatory scrutiny.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for low trading volume and wide bid-ask spreads.
- Higher risk of price manipulation and fraud.
- Uncertain regulatory oversight and compliance.
- Difficulty in obtaining reliable information about the company's operations and financial condition.
- Verify the company's registration and compliance status with regulatory agencies.
- Review available financial statements and assess the company's financial health.
- Research the background and experience of the company's management team.
- Evaluate the company's business model and competitive positioning.
- Assess the potential risks and challenges facing the company.
- Monitor news and developments related to the company and its industry.
- Consult with a qualified financial advisor before making any investment decisions.
- The company has been in operation since 1984.
- Focus on a specific niche market (high-CBD/low-THC hemp oils).
- Development of consumer products under the EUFLORIA brand.
- Engagement in research and development activities.
Common Questions About ACCA
What does Acacia Diversified Holdings, Inc. do?
Acacia Diversified Holdings, Inc. specializes in the extraction, processing, and distribution of medical-grade hemp oils with high CBD and low THC content. The company is also involved in the research and development of botanicals endocannabinoid nutraceuticals, offering a range of medicinal hemp products and dietary supplements. Its consumer products are marketed under the EUFLORIA brand, targeting health and wellness markets through various distribution channels. The company operates within the specialty and generic drug manufacturing sector, focusing specifically on CBD-based products.
What do analysts say about ACCA stock?
As of 2026-03-16, there is no available analyst coverage for Acacia Diversified Holdings, Inc. due to its OTC listing and small market capitalization. Key valuation metrics such as price-to-earnings ratio are not meaningful due to negative earnings. Growth considerations include the company's ability to expand its product line, secure funding, and navigate the evolving regulatory landscape for CBD products. Investors should conduct their own thorough research and consider the inherent risks associated with investing in OTC-listed companies.
What are the main risks for ACCA?
The main risks for Acacia Diversified Holdings, Inc. include intense competition in the CBD market, regulatory uncertainty surrounding CBD products, and challenges in securing funding for ongoing operations. The company's negative profit margin and small market capitalization also pose significant financial risks. Additionally, fluctuations in the price and availability of hemp could impact production costs and profitability. Investors should carefully consider these risks before investing in ACCA.
What are the key factors to evaluate for ACCA?
Acacia Diversified Holdings, Inc. (ACCA) currently holds an AI score of 48/100, indicating low score. Key strength: Focus on high-CBD/low-THC medical grade hemp oils.. Primary risk to monitor: Potential: Intense competition in the rapidly growing CBD market.. This is not financial advice.
How frequently does ACCA data refresh on this page?
ACCA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ACCA's recent stock price performance?
Recent price movement in Acacia Diversified Holdings, Inc. (ACCA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on high-CBD/low-THC medical grade hemp oils.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ACCA overvalued or undervalued right now?
Determining whether Acacia Diversified Holdings, Inc. (ACCA) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ACCA?
Before investing in Acacia Diversified Holdings, Inc. (ACCA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for Acacia Diversified Holdings, Inc.
- OTC market investments carry higher risk due to less regulation.